Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel
https://doi.org/10.37489/2588-0519-2020-S4-81-86
Abstract
There currently exists no published robust data which would confirm effectiveness and safety of hydroxychloroquine in pre- and postexposure prophylaxis of SARS-CoV-2 infection. Taking into account in vitro data, which indicates inhibitory activity of hydroxychloroquine against SARS-CoV-2, and interim guidelines by the Ministry of Health of the Russian Federation, hydroxychloroquine can be considered as postexposure prophylaxis among healthcare personnel who have been in contact with patients with laboratory confirmed SARS-CoV-2, provided no contraindications and significant drug interactions are present. Safety monitoring should be performed before prescribing and during the course of treatment (ECG, total blood count and blood biochemistry, ophthalmologist evaluation before long-term treatment).
About the Authors
V. A. Otdelenov
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770
Moscow
A. V. Krykov
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Kryukov Alexander V. – Candidate of Medical Sciences, assistant of the Department of Oncology and palliative medicine of the Department of Clinical Pharmacology and Therapy. SPIN code: 1568-4967
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. State register of medicines. Query «hydroxychloroquine», search by MNN. (In Russ). Доступно по: https://clck.ru/RBf9h Ссылка активна на 14.05.2020
2. State register of medicines. The drug Plakvenil. (In Russ). Доступно по: https://clck.ru/RBf8n Ссылка активна на 14.05.2020
3. Yao X, Ye F, Zhang M et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. DOI: 10.1093/cid/ciaa237
4. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. DOI: 10.1186/1743-422X-2-69
5. Liu J, Cao R, Xu M et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18;6:16. DOI: 10.1038/s41421-020-0156-0
6. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8. DOI: 10.1016/j.bbrc.2004.08.085.
7. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. DOI: 10.1016/j.ijantimicag.2020.105938
8. THE PROVISIONAL GUIDELINES. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 6th ed., Moscow: Ministry of health of the Russian Federation, 2020. (28.04.2020) (In Russ). Доступно по: URL: https://clck.ru/NCM6x Ссылка активна на 14.05.2020
9. Devaux CA, Rolain JM, Colson P et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. DOI 10.1016/j.ijantimicag.2020.105938
10. Barber BE. Chloroquine and Hydroxychloroquine. In: Grayson ML, ed. Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 7th ed. Boca Raton, FL: CRC Press; 2018: 3030-48.
11. Sahraei Z, Shabani M, Shokouhi S et al. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020 Apr;55(4):105945. DOI: 10.1016/j.ijantimicag.2020.105945
12. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. DOI: 10.1093/jac/dkaa114
13. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. [Internet]. [cited 2002 May 14] Available from: https://covid19treatmentguidelines.nih.gov/
14. Coronavirus (COVID-19) Update: FDA Reiterates Importance of Close Patient Supervision for ‘Off-Label’ Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart Rhythm Problems [Internet]. [cited 2002 May 14] Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-reiterates-importance-close-patientsupervision-label-use
15. HRS COVID-19 Task Force Update: April 21, 2020. [Internet]. [cited 2002 May 14] Available from: https://www.hrsonline.org/COVID19Challenges-Solutions/hrs-covid-19-task-force-update-april-21-2020
16. Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs. Detailed recommendations for interactions with experimental COVID-19 therapies. [Internet]. [cited 2002 May 14] Available from: https://www.covid19-druginteractions.org/
17. Clinicaltrials.gov Search Results for «Hydroxychloroquine prophylaxis healthcare | COVID-19» [Internet]. [cited 2002 May 14] Available from: https://clck.ru/RBfCC
18. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc. 2020 Jun;95(6):1213-1221. DOI: 10.1016/j.mayocp.2020.03.024
Review
For citations:
Otdelenov V.A., Krykov A.V., Sychev D.A. Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):81-86. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-81-86
Views:
1723
Email this article 